source
- Seven deaths linked to Neurocrine’s Prader-Willi drug Vykat raise safety concernsClinicians have warned that seven patients who received Neurocrine Biosciences' recently approved Prader-Willi syndrome therapy Vykat have died, prompting a new safety alert for the patient communi…
- Aardvark Therapeutics abandons phase 3 trials after workforce cuts and FDA holdAardvark Therapeutics announced it is walking away from its recently terminated phase 3 trials, stating there are no plans to resume them as originally designed. The decision follows a reduction i…